Pharmaceutical News

RSS

Pharmatek Laboratories meets DEA requirements for developing and manufacturing controlled substances

Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has successfully met Drug Enforcement Agency (DEA) requirements to be registered for the development and manufacture of Schedule IV and V controlled substances.

17 Feb 2010

Menopause supplement to bring body back into balance

Whitemark Homes, Inc., is pleased to announce a satisfaction guaranteed top selling product line by Ribbon Naturals Corp., complete system Menopause Solutions. A solution for women who are dissatisfied with the results they receive from common, everyday menopause supplements. Now there is a supplement for menopause that brings the body back into balance.

17 Feb 2010

FDA approved cannabis medicines needed for veterans to relieve symptoms of PTSD

Cannabis Science Inc., an emerging pharmaceutical cannabis company, is reviewing interim results of its survey from over 1400 people, US military veterans and others who responded to our PTSD survey. The survey is still available for a limited time online on the www.cannabisscience.com website for all those who still wish to participate.

17 Feb 2010

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Soligenix, Inc., a late-stage biotechnology company, announced today that it has received a Hong Kong patent which addresses its Lipid Polymer Micelle (LPM™) technology for the improved oral delivery of drugs. The issued Hong Kong patent, HK 1071054, entitled "Stabilized Reverse Micelle Compositions and Uses Thereof" covers lipid structures (reverse micelles) that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.

17 Feb 2010

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2009.

17 Feb 2010

UKONS publishes position statement on safe, effective use of oral anticancer medicines

A position statement from the UK Oncology Nursing Society (UKONS) on the safe, effective use of oral anticancer medicines was published online on 5 February 2010 by ecancermedicalscience.

17 Feb 2010

AHF to protest Merck’s Isentress pricing and policies at CROI

AIDS Healthcare Foundation (AHF) will host a protest Wednesday morning, February 17 at 8:00am targeting Merck and Co. Pharmaceuticals over the pricing and policies for its key HIV/AIDS drug, Isentress, the most expensive first-line AIDS treatment in the US, during the 17th Conference of Retroviruses and Opportunistic Infections (CROI) in San Francisco.

17 Feb 2010

AMAG's Feraheme use on the rise

BioTrends Research Group, Inc. released Wave 3 of its LaunchTrends®: Feraheme report, the third in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and product satisfaction.

17 Feb 2010

New book by 12 world-leading scientists calls for renewed approach to drug policy

Drug policy - or really, the way our society controls and provides interventions for both legal and illegal psychoactive substances - is one of those things that seems inherently controversial.

17 Feb 2010

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).

17 Feb 2010

Research suggests scorpion venom could be an alternative to morphine painkiller

Scorpion venom is notoriously poisonous ― but it might be used as an alternative to dangerous and addictive painkillers like morphine, a Tel Aviv University researcher claims.

17 Feb 2010

Effectiveness of influenza vaccines in older people: No clear conclusions

Evidence for the safety and efficacy of influenza vaccines in the over 65s is poor, despite the fact that vaccination has been recommended for the prevention of influenza in older people for the past 40 years. These are the conclusions of a new Cochrane Systematic Review.

17 Feb 2010

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

Researchers use new strategy to develop cancer vaccines

Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences, Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells.

17 Feb 2010

ECR Pharmaceuticals to promote Urocit-K 15mEq tablets to primary care physicians

Hi-Tech Pharmacal Co., Inc. announced today that its branded marketing subsidiary, ECR Pharmaceuticals will promote Urocit®-K 15mEq, potassium citrate extended release tablets to primary care physicians beginning in April, 2010. Hi-Tech has a license agreement with Mission Pharmacal Company, which will promote the product to Urologists.

17 Feb 2010

Covidien's Exalgo NDA: FDA sets new PDUFA action date

Covidien today announced that the U.S. Food and Drug Administration has set a new action date of March 1, 2010, under the Prescription Drug User Fee Act (PDUFA) for the review of the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) Extended-Release Tablets, (CII).

17 Feb 2010

Covidien, IAE POLATOM announce agreement to augment supply of Mo 99 to produce Tc 99m

Covidien, a leading global provider of healthcare products, and the Institute of Atomic Energy in Poland today announced an agreement to augment and further diversify Covidien’s supply of Molybdenum 99 (Mo 99) to produce the medical isotope Technetium 99m (Tc 99m).

17 Feb 2010

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program is also designed to help ensure the appropriate administration of these drugs, which they receive to treat anemia that can occur as a result of chemotherapy.

17 Feb 2010

USPTO issues two new patents for EKR Therapeutics' RTU Cardene I.V. Premixed Injection

EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that the US Patent and Trademark Office has issued two new patents covering methods of treatment and methods of preparation for the Company’s Ready-to-Use (RTU) Cardene® I.V. (nicardipine hydrochloride) Premixed Injection.

17 Feb 2010

AZ&Me Prescription Savings programs help 13% more patients in 2009

AstraZeneca announced today that it provided $769.6 million in savings to 507,475 patients in the United States last year through its AZ&Me™ Prescription Savings programs.

17 Feb 2010

Pharmaceutical News

Pharmatek Laboratories meets DEA requirements for developing and manufacturing controlled substances

Menopause supplement to bring body back into balance

FDA approved cannabis medicines needed for veterans to relieve symptoms of PTSD

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

UKONS publishes position statement on safe, effective use of oral anticancer medicines

AHF to protest Merck’s Isentress pricing and policies at CROI

AMAG's Feraheme use on the rise

New book by 12 world-leading scientists calls for renewed approach to drug policy

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

Research suggests scorpion venom could be an alternative to morphine painkiller

Effectiveness of influenza vaccines in older people: No clear conclusions

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Researchers use new strategy to develop cancer vaccines

ECR Pharmaceuticals to promote Urocit-K 15mEq tablets to primary care physicians

Covidien's Exalgo NDA: FDA sets new PDUFA action date

Covidien, IAE POLATOM announce agreement to augment supply of Mo 99 to produce Tc 99m

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

USPTO issues two new patents for EKR Therapeutics' RTU Cardene I.V. Premixed Injection

AZ&Me Prescription Savings programs help 13% more patients in 2009

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News